亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Small molecule inhibitors of IRAP

总结: Monash University researchers have identified and validated a novel anti-fibrosis target - IRAP. Inhibition of this target with the proprietary small molecule lead series completely reversed cardiac and renal fibrosis in clinically relevant disease models. We nows eek a partner to develop novel lead candidate inhibitors as safe and effective anti-fibrotic drugs.

技术优势: - Potential to develop ‘Best in Disease’ anti-fibrotic drugs that reverse existing fibrotic lesions
- ‘Proof of Mechanism’ with in vivo efficacy for small molecule inhibitors
- Differentiated and vasoprotective mechanism of action

详细技术说明: Researchers from the Monash BioMedicine Discovery Institute (A/Prof. Siew Chai, Prof. Rob Widdop & Dr. Tracey Gaspari) and Monash Institute of Pharmaceutical Sciences (A/Prof. Phil Thompson) have identified IRAP as a new target for the treatment of cardiac, kidney, liver and potentially other organ fibrosis. IRAP is an extracellular protein that is ‘druggable’ with small molecule inhibitors. A compelling body of evidence supporting proof-of-mechanism and validation with a lead series has shown that IRAP inhibition can prevent and reverse fibrosis.
- IRAP deficiency/inhibition protects against the development of cardiac and renal fibrosis in aged mice and cardiac fibrosis in Ang II-treated mice.
- IRAP inhibition completely reverses cardiac fibrosis in aged mice, with corresponding decreases in inflammatory and oxidative stress markers and increases in NO bioavailability.
- IRAP deficiency/inhibition protects against ischemia-reperfusion damage and improves function of aged ischemic hearts.
- IRAP inhibition protects and reverses age mediated renal fibrosis and high salt induced cardiac/renal fibrosis

其他: Monash seeks a partner to optimise the lead series and develop new drug candidates against this exciting target. The Monash team has extensive experience in IRAP and fibrosis biology, having an array of in-house models including in vitro target screen, functional assay, specific knock-out models, fibrosis and other pathological models, pus target SAT and preclinical profiling experience.

欲了解更多信息，请点击这里